SCHEMBL3761010

SCHEMBL3761010

COc1cc(C(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.47
PARP1 P09874 1/20 0.45
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HRH3 Q9Y5N1 8/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
KMT2A Q03164 2/20 0.41
KCNH2 Q12809 2/20 0.41
SLC6A4 P31645 1/20 0.41
F10 P00742 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006111 0.90 HRH3 (0.48) PKMKDM4EALDH1A1HRH3ACACB
SCHEMBL3769940 0.88 HRH3 (0.45) PKMKDM4EALDH1A1HRH3ACACB
SCHEMBL3774645 0.82 PKM (0.69) PKMKDM4EALDH1A1KMT2A
SCHEMBL3764970 0.81 KDM4E (0.53) PKMKDM4EALDH1A1HRH3SLC6A4
SCHEMBL3768862 0.81 HRH3 (0.48) KDM4EALDH1A1HRH3KCNH2SLC6A4
SCHEMBL3780656 0.81 KMT2A (0.63) PKMKDM4EALDH1A1KMT2A
SCHEMBL3770028 0.79 HPGD (0.50) PKMKDM4EALDH1A1HRH3
SCHEMBL13005925 0.78 KMT2A (0.57) PKMKDM4EALDH1A1HRH3KMT2A
SCHEMBL3761199 0.78 ALDH1A1 (0.64) KDM4EALDH1A1KMT2AF10
SCHEMBL3771705 0.78 PKM (0.43) PKMKDM4EALDH1A1HRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PKM 219/4885PARP1 3744/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.